East Montgomery Times

Fox Chase Cancer Center has announced that three of its faculty members have been named to the 2024 list of Highly Cited Researchers by Clarivate. This recognition highlights their significant contributions to cancer research and treatment.

"We are proud to have in our midst researchers and physicians whose work plays an essential role in the development and improvement of cancer treatment worldwide," said the Cancer Center Director. "With three of our scientists named to this list, Fox Chase is well represented as a place where cutting-edge, meaningful cancer research is being done every day."

Among those honored is Galluzzi, an Associate Professor who was nominated in two fields: Immunology and Molecular Biology & Genetics. This distinction is shared by only 6% of the honorees.

Borghaei, Chief of the Division of Thoracic Medical Oncology and a Professor at Fox Chase, specializes in lung cancer research. His lab focuses on developing new treatments using immunotherapy and monoclonal antibodies. He also participates actively in clinical trials.

Plimack serves as Deputy Director at Fox Chase and specializes in treating kidney, bladder, and prostate cancers. Her research aims at developing new therapies for bladder and kidney cancer.

The Highly Cited Researchers list has been recognizing influential clinicians and scientists since 2001. It uses data from the Web of Science Core Collection citation index along with qualitative analysis by bibliometric experts at Clarivate's Institute for Scientific Information.

Clarivate explains that the annual listing identifies individuals who have authored "multiple Highly Cited Papers which rank in the top 1% by citations for their field(s) and publication year." However, papers with more than 30 authors are excluded from consideration to ensure individual contributions are recognized accurately.

Galluzzi's work examines cellular pathways related to stress response and organism stability, focusing on anticancer immunity. In addition to his role at Fox Chase, he holds positions with the European Academy for Tumor Immunology and the European Research Institute for Integrated Cellular Pathology.